new report poland b medical cannabis b market

New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery

✦ New
CED Clinical Relevance
#55 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
PolicyResearchIndustryPainDosing
Why This Matters
If you are a medical cannabis patient in Europe, Poland’s regulatory reversal and recovery is a reminder that access to your medication can be interrupted quickly by policy changes, making it essential to stay informed about local prescribing rules and maintain open communication with your physician.
Clinical Summary

Poland’s medical cannabis market demonstrated resilience following a regulatory disruption that required patients to attend in-person consultations before receiving prescriptions, a policy shift that temporarily curtailed access for many patients who had relied on telemedicine pathways. The market’s recovery reflects both sustained patient demand and the adaptability of prescribing infrastructure when regulatory frameworks stabilize. This trajectory mirrors patterns seen in other European markets where access restrictions, even temporary ones, reshape patient behavior and supply chains in ways that take months to fully normalize.

Dr. Caplan’s Take
“Requiring in-person consultations for cannabis prescriptions without adequate clinical justification is a access barrier dressed up as patient safety policy, and the market recovery data simply confirms that patient need does not disappear when bureaucracy gets in the way.”
Clinical Perspective

🔬 Poland’s requirement for in-person consultations represents a meaningful shift toward standardized clinical oversight in medical cannabis prescribing. While telemedicine has expanded access in many jurisdictions, face-to-face evaluation allows clinicians to conduct comprehensive physical examinations and better assess patient suitability for cannabis therapeutics. The market recovery data suggests patients and providers have adapted to these requirements, indicating that robust regulatory frameworks need not impede legitimate medical access. This model may offer insights for other European healthcare systems balancing accessibility with clinical accountability in cannabis medicine.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →